Collegium Pharmaceutical, Inc. (NASDAQ:COLL) was downgraded by equities researchers at BidaskClub from a “hold” rating to a “sell” rating in a research note issued to investors on Friday.

A number of other research firms also recently weighed in on COLL. Zacks Investment Research downgraded shares of Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Tuesday, July 11th. Piper Jaffray Companies set a $14.00 price target on shares of Collegium Pharmaceutical and gave the company a “buy” rating in a research report on Tuesday, July 25th. ValuEngine upgraded shares of Collegium Pharmaceutical from a “strong sell” rating to a “sell” rating in a research report on Thursday, June 22nd. Janney Montgomery Scott reiterated a “buy” rating and issued a $25.00 price target on shares of Collegium Pharmaceutical in a research report on Monday, June 12th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $25.00 price target on shares of Collegium Pharmaceutical in a research report on Friday, June 9th. Three investment analysts have rated the stock with a sell rating and five have assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $21.33.

Collegium Pharmaceutical (COLL) traded up 2.44% during mid-day trading on Friday, hitting $11.32. The company had a trading volume of 398,002 shares. The company’s market cap is $333.46 million. The company’s 50 day moving average price is $12.18 and its 200-day moving average price is $12.12. Collegium Pharmaceutical has a one year low of $7.37 and a one year high of $20.55.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings data on Wednesday, May 10th. The specialty pharmaceutical company reported ($0.79) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.98) by $0.19. The firm had revenue of $2.17 million for the quarter, compared to the consensus estimate of $3.55 million. Equities research analysts anticipate that Collegium Pharmaceutical will post ($3.14) EPS for the current fiscal year.

WARNING: “Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Downgraded by BidaskClub” was posted by American Banking News and is owned by of American Banking News. If you are accessing this article on another domain, it was illegally copied and republished in violation of international trademark & copyright law. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/08/06/collegium-pharmaceutical-inc-nasdaqcoll-downgraded-by-bidaskclub.html.

In other Collegium Pharmaceutical news, insider Paul Brannelly purchased 10,000 shares of the company’s stock in a transaction dated Friday, May 12th. The stock was bought at an average cost of $9.18 per share, for a total transaction of $91,800.00. Following the completion of the transaction, the insider now owns 110,227 shares in the company, valued at $1,011,883.86. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 25.76% of the stock is currently owned by insiders.

Several large investors have recently added to or reduced their stakes in COLL. Dynamic Technology Lab Private Ltd acquired a new stake in Collegium Pharmaceutical during the first quarter worth $238,000. American International Group Inc. increased its position in shares of Collegium Pharmaceutical by 27.8% in the first quarter. American International Group Inc. now owns 9,948 shares of the specialty pharmaceutical company’s stock valued at $100,000 after buying an additional 2,163 shares in the last quarter. Pier Capital LLC increased its position in shares of Collegium Pharmaceutical by 11.1% in the first quarter. Pier Capital LLC now owns 366,064 shares of the specialty pharmaceutical company’s stock valued at $3,683,000 after buying an additional 36,435 shares in the last quarter. Trexquant Investment LP purchased a new position in shares of Collegium Pharmaceutical during the first quarter valued at approximately $259,000. Finally, Bank of New York Mellon Corp increased its position in shares of Collegium Pharmaceutical by 6.1% in the first quarter. Bank of New York Mellon Corp now owns 65,305 shares of the specialty pharmaceutical company’s stock valued at $656,000 after buying an additional 3,775 shares in the last quarter. Institutional investors own 82.36% of the company’s stock.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

Analyst Recommendations for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.